*This estimate derives from Eli Lilly's SURMOUNT-4 clinical trial results, which showed 20% average weight loss over 36 weeks among people who utilized a maximum tolerated dose of 10 mg or 15 mg once-weekly. The starting dose of 2.5 mg Zepbound was increased by 2.5 mg every four weeks until maximum tolerated dose was achieved. Treatment was given in addition to diet and exercise.